Evidence map›Paper›PMID 31141307›Full record

ArticleBJU international2019

Use of multiparametric magnetic resonance imaging and fusion-guided biopsies to properly select and follow African-American men on active surveillance.

Jonathan B Bloom, Amir H Lebastchi, Samuel A Gold, Graham R Hale, Thomas Sanford, Sherif Mehralivand, Michael Ahdoot, Kareem N Rayn, Marcin Czarniecki, Clayton Smith and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Jonathan B BloomUrologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.ORCID 0000-0003-4647-4132
Amir H LebastchiUrologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.
Samuel A GoldUrologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.
Graham R HaleUrologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.
Thomas SanfordUrologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.
Sherif MehralivandUrologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.
Michael AhdootUrologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.
Kareem N RaynUrologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.
Marcin CzarnieckiMolecular Imaging Program, NCI, NIH, Bethesda, MD, USA.
Clayton SmithMolecular Imaging Program, NCI, NIH, Bethesda, MD, USA.
Vladimir ValeraUrologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.
Bradford J WoodCenter for Interventional Oncology, NCI, NIH, Bethesda, MD, USA.
Maria J MerinoLaboratory of Pathology, NCI, NIH, Bethesda, MD, USA.
Peter L ChoykeMolecular Imaging Program, NCI, NIH, Bethesda, MD, USA.
Howard L ParnesDivision of Cancer Prevention, NCI, NIH, Bethesda, MD, USA.
Baris TurkbeyMolecular Imaging Program, NCI, NIH, Bethesda, MD, USA.
Peter A PintoUrologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.
National Institutes of Health · USCenter for Cancer Research · US

Funding

Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
Prostate SectionZIABC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2009 to 2025
$15.2M
Translational Surgical PathologyZIESC000853 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI MERINO, MARIA · 2009 to 2025
$4.3M
Prostate Cancer ImagingZ01BC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2005 to 2008
$2.1M
Intramural NIH HHS Z01 BC010655Intramural NIH HHS ZIA BC011081Intramural NIH HHS ZID BC011242Intramural NIH HHS ZIE SC000853
6 · The paper itself

Abstract

objectivesTo determine the rate of Gleason Grade Group (GGG) upgrading in African-American (AA) men with a prior diagnosis of low-grade prostate cancer (GGG 1 or GGG 2) on 12-core systematic biopsy (SB) after multiparametric magnetic resonance imaging (mpMRI) and fusion biopsy (FB); and whether AA men who continued active surveillance (AS) after mpMRI and FB fared differently than a predominantly Caucasian (non-AA) population. PATIENTS AND

methodsA database of men who had undergone mpMRI and FB was queried to determine rates of upgrading by FB amongst men deemed to be AS candidates based on SB prior to referral. After FB, Kaplan-Meier curves were generated for AA men and non-AA men who then elected AS. The time to GGG upgrading and time continuing AS were compared using the log-rank test.

resultsAA men referred with GGG 1 disease on previous SB were upgraded to GGG ≥3 by FB more often than non-AA men, 22.2% vs 12.7% (P = 0.01). A total of 32 AA men and 258 non-AA men then continued AS, with a median (interquartile range) follow-up of 39.19 (24.24-56.41) months. The median time to progression was 59.7 and 60.5 months, respectively (P = 0.26). The median time continuing AS was 61.9 months and not reached, respectively (P = 0.80).

conclusionsAA men were more likely to be upgraded from GGG 1 on SB to GGG ≥3 on initial FB; however, AA and non-AA men on AS subsequently progressed at similar rates following mpMRI and FB. A greater tendency for SB to underestimate tumour grade in AA men may explain prior studies that have shown AA men to be at higher risk of progression during AS.

Indexed as

Black or African AmericanProstatic NeoplasmsAgedHumansImage-Guided BiopsyMaleMiddle AgedMultiparametric Magnetic Resonance ImagingProstateRetrospective StudiesWatchful Waitingactive surveillanceAfrican-Americanfusion biopsymulti-parametric MRI#PCSM#ProstateCancer

Identifiers

PMID31141307
PMCPMC8288555
OpenAlexW2946844241

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.